Cargando…

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera...

Descripción completa

Detalles Bibliográficos
Autores principales: Soni, Abhishek, Bansal, Nupur, Kaushal, Vivek, Chauhan, Ashok Kr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612/
https://www.ncbi.nlm.nih.gov/pubmed/25815059
http://dx.doi.org/10.3332/ecancer.2015.517
_version_ 1782362901434073088
author Soni, Abhishek
Bansal, Nupur
Kaushal, Vivek
Chauhan, Ashok Kr
author_facet Soni, Abhishek
Bansal, Nupur
Kaushal, Vivek
Chauhan, Ashok Kr
author_sort Soni, Abhishek
collection PubMed
description Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.
format Online
Article
Text
id pubmed-4370612
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-43706122015-03-26 Current management approach to hidradenocarcinoma: a comprehensive review of the literature Soni, Abhishek Bansal, Nupur Kaushal, Vivek Chauhan, Ashok Kr Ecancermedicalscience Review Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials. Cancer Intelligence 2015-03-19 /pmc/articles/PMC4370612/ /pubmed/25815059 http://dx.doi.org/10.3332/ecancer.2015.517 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Soni, Abhishek
Bansal, Nupur
Kaushal, Vivek
Chauhan, Ashok Kr
Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title_full Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title_fullStr Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title_full_unstemmed Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title_short Current management approach to hidradenocarcinoma: a comprehensive review of the literature
title_sort current management approach to hidradenocarcinoma: a comprehensive review of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612/
https://www.ncbi.nlm.nih.gov/pubmed/25815059
http://dx.doi.org/10.3332/ecancer.2015.517
work_keys_str_mv AT soniabhishek currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature
AT bansalnupur currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature
AT kaushalvivek currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature
AT chauhanashokkr currentmanagementapproachtohidradenocarcinomaacomprehensivereviewoftheliterature